GIOSTAR: The Shining Star of Modern Healthcare Industry & BioTech
The human body can have losses in the functioning of organs because of tissue losses caused by diseases or injuries. This predicament enforces demands for the development of treatments that can regenerate tissues, and thereby, decrease reliance on organ transplantations. Regenerative medicine is a rapidly evolving medical field that deploys doctrines of engineering and life sciences to help regenerate damaged or diseased tissues, thus restoring the functions of an organ. This field has the potential to develop whole organs in the future.
Co-Founded by Dr. Anand Srivastava, Chairman, and Mr. Deven Patel, CEO, Global Institute of Stem Cell therapy and Research (GIOSTAR) is the world’s leading stem cell research institution located in San Diego, CA, USA and has been involved in stem cell research work for over 20 years. GIOSTAR is the fine combination of renowned scientists and clinicians involved in the stem cell research work with the concept of bench (research) to bedside (clinic) philosophy. The company has generated the very pure Neural Precursor Cells (NPCs) which may be used to treat many neural diseases. Also, it is leading in the field of generating patient-specific induced Pluripotent Stem Cells (iPSCs) which have the ability to differentiate into cells of any lineage. These cells have the potential to be used as an alternative to ES cells. The company is also working over a decade to unfold the mystery of biology of aging has become the world leader in aging management technologies and therapeutics (commonly referred to as anti-aging) whereby patients utilize its aging management services as proactive, preventative stem cell therapies against debilitating diseases associated with the increasing aging population.
The Experts behind GIOSTAR:
Dr. Srivastava is the Chairman and chief scientific officer (CSO) of GIOSTAR whose success is rooted in his unique background of expertise in stem cell biology, protein biochemistry, molecular biology, immunology, in utero transplantation of stem cells, tissue targeting, gene therapy, and clinical research. He has been associated with leading universities and research institutes in the USA. While working at University of California San Diego (UCSD), University of California Irvine (UCI), Salk Research Institute, San Diego, Burnham Institute For Medical Research, San Diego, University of California Los Angeles (UCLA), USA, he has helped develop several research programs, and has an extensive research experience in the field of Stem cell sciences, which is documented by several publications in revered scientific journals.
There are many scientists who can work in narrowly defined fields but only a few have the broad and multidisciplinary experience to carry out clinical research in a field as challenging as Stem cell biology, cancer, and gene therapy. Dr. Srivastava’s wide-spectrum expertise is rare in clinical research, perfectly crafted to fit ideally with the GIOSTAR projects on Stem cell transplant, cancer, and gene therapy research.
Mr. Deven Patel, based in San Diego, California, U.S.A, is the CEO & Co-founder of GIOSTAR. Mr. Patel is a proactive and compassionate business leader.
Using Stem Cell to Cure Incurables:
GIOSTAR’s vision is to make this most advanced science and treatment available, accessible, and affordable to the masses around the world, and to provide solutions to incurable conditions. The team behind the institute includes international groups of leading researchers, doctors, and scientists in the field of stem cells. The members are only those with the highest academic, medical, and professional credentials.
GIOSTAR has developed clinical protocols of stem cell therapies for treating autoimmune, degenerative, and metabolic diseases. Also, have developed immune-therapy protocols for treating cancer.
According to Dr. Srivastava, GIOSTAR is a world leader in the use of various types of stem cells, such as mobilized stem cells from blood, bone marrow, CD34-positive, and mesenchymal stem cells. He asserts, “These stem cells may be used in the treatment of certain types of immunological and blood-related diseases. GIOSTAR has also pioneered research and studies for heart infarct repair, limb ischemia modelling with endometrial regenerative cells, and the generation of universal red cells.” The company also generates blood stem cells from stem cells which may have abilities to manage the blood related diseases such as beta-thalassemia and sickle cell anemia.
An Advice to Hear Out:
As per Dr. Srivastava, under the influence of market dictation, influenced by their race of making a ridiculous amounts of profits, many Pharma and BioTech companies are failing to understand and missing to utilize the healing potential of a human body, and thereby, failing to heal the humanity from the root causes of the diseases.
His advice to the budding leaders in the Pharma & Biotech industry is to operate from a position of compassion for humanity, and should not be guided singularly by the profits. He further stresses, “This way you will achieve success way beyond your wildest dreams.”
GIOSTAR is one of the first companies in the world to get US FDA approval to treat COVID-19 patients with stem cells under FDA compassionate use program in April 2020.
GIOSTAR was able to save the life of a COVID-19 patient who had no hope whatsoever to survive the virus attack.
Leading the Market with Innovation:
GIOSTAR was the first in the world to demonstrate the significance of stem cell use for the development of therapies for many types of diseases rooted in degenerating tissues and organs. The research papers on these therapies have been published by several revered journals of medical science.
The basic GIOSTAR philosophy is focused on the compassionate approach to heal humanity from many incurable and devastating diseases. According to Dr. Srivastava, GIOSTAR has no competition as it provides cutting-edge science guided treatments it can provide, and others even cannot come close to what the GIOSTAR team has been able to achieve. He says, “Our edge is granted by our pioneering and ground-breaking research works of last 20 years in the field of stem cell science, gene therapy, and cancer research.”
Future for GIOSTAR:
With the advancements in the field of stem cell sciences, the management’s range of interests at GIOSTAR is expanding every single day. While its therapeutic programs are focused exclusively on the transplantation of adult tissue-derived stem cells and progenitor cells for several degenerative diseases of different organs, the team of experts believes there is a utility in all types of stem cells and their progeny.
GIOSTAR is in the process of taking one of its Post-Covid treatment companies public. GIOSTAR also created another clinical trial company (Celebration Life Sciences) that will conduct several clinical trials with USFDA using its proprietary stem cell technology platform.
First time in 20 years, GIOSTAR is creating very lucrative investment opportunities for general public to participate in GIOSTAR group of companies.
Source : https://thebusinessfame.com/giostar-the-shining-star-of-modern-healthcare-industry-biotech/